Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study

Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study

Background: COVID-19 continues to pose a threat to immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 with the benefit of a prolonged half-life. Although approved for COVID-19 prevent...

Full description

Bibliographic Details
Main Authors: Dimitrios Basoulis, Elpida Mastrogianni, Georgios Karamanakos, Aikaterini Gkoufa, Vasiliki E. Georgakopoulou, Sotiria Makrodimitri, Maria N. Gamaletsou, Antonios Markogiannakis, Nikolaos V. Sipsas
Format: Article
Language:English
Published: MDPI AG 2024-08-01
Series:Viruses
Subjects:
COVID-19
monoclonal antibodies
tixagevimab/cilgavimab
immunocompromised patients
Online Access:https://www.mdpi.com/1999-4915/16/8/1345

Internet

https://www.mdpi.com/1999-4915/16/8/1345

Similar Items